Aromasine

Quick links to important sections

Aromasine

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aromasine

Property Description
Active ingredient Exemestane
Form Oral tablet (film-coated)
Pharmacological class Steroidal Aromatase Inactivator / Antineoplastic Agent
General purpose Estrogen level reduction in endocrine therapy
Origin Synthetic compound (Steroidal structure)

What Type of Medicine is Aromasin (Exemestane)?

Aromasin is the trade name for the drug containing the active ingredient Exemestane, which is formally classified as a steroidal aromatase inactivator and an antineoplastic agent. This medicine belongs to the category of endocrine therapy agents and is strictly available as a prescription-only medicine. Exemestane's key differentiating feature is its synthetic steroidal structure, which is chemically similar to natural precursor hormones. This structural property distinguishes it from non-steroidal inhibitors like anastrozole or letrozole.

Composition and Physical Form of Aromasin

The active compound Exemestane is supplied as an oral tablet that is film-coated. This presentation defines the oral route of administration. The tablet's composition includes the active ingredient, Exemestane, alongside necessary pharmaceutical excipients used to form a stable and easily administered solid preparation. The selection of a film-coated tablet ensures the stability required for the synthetic steroidal compound, facilitating a simple administration method.

Aromasin's General Purpose: Endocrine Therapy and Estrogen Reduction

The general purpose of Aromasin is to reliably and significantly lower the level of estrogen circulating throughout the body, making it a pivotal component of endocrine therapy. Exemestane achieves this because it acts as an irreversible enzyme inhibitor. It permanently deactivates the aromatase enzyme, which is the primary catalyst for the conversion of precursor hormones into estrogen. The medicine provides a systemic method for hormone suppression to achieve the intended therapeutic outcome.

Regulatory References

  1. DailyMed Label: EXEMESTANE tablet, film coated

What side effects are possible with Aromasine?

Possible Side Effects and Safety Information

The official safety profile for Aromasine (Exemestane) is derived from government regulatory documents and is structured by adverse reaction frequency and affected organ system. The majority of documented side effects are consistent with the medicine's role as a potent estrogen-lowering agent in postmenopausal women.

Official Classification of Adverse Reactions

Adverse reactions are classified according to incidence observed in clinical studies:

  • Very Common (Affecting ge1/10 patients): Hot flushes, musculoskeletal and joint pain (including arthralgia), fatigue, insomnia, headache, increased sweating (hyperhidrosis), and abdominal pain. Laboratory investigations frequently show elevated hepatic enzymes and blood bilirubin.
  • Common (Affecting ge1/100 to <1/10 patients): Osteoporosis, bone fracture, vomiting, diarrhea, constipation, dyspepsia, peripheral oedema, rash, alopecia, and dizziness.
  • Uncommon and Rare: Less frequent reactions include hypersensitivity, leukopenia, thrombocytopenia (uncommon), and rare reports of hepatitis, cholestatic hepatitis, and acute generalised exanthematous pustulosis.

Safety Considerations and Constraints

The regulatory profile highlights specific constraints and systemic risks. Serious adverse reactions documented include the potential for bone fractures associated with reduced Bone Mineral Density (BMD) over time, and rare reports of cardiac ischemic events. The medicine is contraindicated for women who are pre-menopausal or pregnant. Official safety information states that drowsiness, asthenia, and dizziness may impair the ability to drive or operate machinery. Furthermore, specific baseline assessments, such as BMD monitoring, are recommended for women at risk of osteoporosis at the start of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation details the documented manifestations and required emergency procedures in the event of an overdose of Aromasine (exemestane).

Documented Overdose Presentations

Clinical experience with high doses (up to 200 mg per day) has documented specific gastrointestinal symptoms, including vomiting and diarrhea. Acute exposure to excessive doses has not been associated with a specific acute life-threatening toxic syndrome, and a lethal dose has not been established in regulatory reports. The observed clinical signs are generally consistent with the known adverse reaction profile of the medicine.

Emergency Actions and Management

Immediate professional medical assistance must be sought for any suspected or confirmed overdose. In the United States, patients are advised to contact a certified Poison Control Center for guidance.

Crucially, no specific antidote is known for Exemestane overdose. Therefore, official management is centered on symptomatic and supportive treatment. Procedural considerations, particularly for recent ingestion, may include measures to limit systemic absorption, such as gastric lavage or the administration of activated charcoal. All patients must receive frequent monitoring of vital signs, and ECG surveillance is officially listed as a required monitoring procedure during the management period.

Therapeutic Uses of Aromasine

What Aromasin Treats: Main Uses and Benefits

Aromasin (exemestane) is commonly used in the management of hormone-sensitive breast cancer in postmenopausal women.


Endocrine Management and Key Benefits

Aromasin is applied as adjuvant endocrine therapy for estrogen-receptor positive (ER+) early breast cancer, as a second-line treatment for advanced cancer that has progressed on prior hormonal therapy, and is also considered relevant for reducing the risk of invasive breast cancer in high-risk, healthy women.

In the early-stage setting, this intervention is used for managing the risk of disease recurrence, which is a systemic imbalance that interferes with daily functioning. The therapeutic benefit is supporting the patient's period of being disease-free and may assist in lowering the likelihood of cancer returning.

“The medication is applied when appropriate in contexts where additional symptomatic support is needed to address hormone-driven tumor activity.”

For advanced cases, Aromasin provides supportive relief that helps address the progression of the hormone-sensitive tumor, assisting with maintaining functional stability in the patient.

Quick Fact: Therapeutic Support for Hormone-Sensitive Conditions This therapy is relevant for easing conditions characterized by systemic imbalance.

Regulatory References

  1. FDA Drug Label for Exemestane

Eligibility and Restrictions for Use

Who Can and Cannot Use Aromasine (Exemestane)?

Eligibility for Aromasine is strictly defined by regulatory bodies based on a patient's hormonal status and specific health conditions.


Populations Allowed and Contraindicated

Population Status Official Eligibility Ruling
Eligible Population Postmenopausal women (natural or induced status).
Absolute Contraindication Premenopausal women, women who are pregnant or lactating, and patients with a known hypersensitivity to the active substance or excipients.

Age and Condition Restrictions

  • Children and Adolescents: Use is not recommended as safety and effectiveness have not been established.
  • Hepatic and Renal Impairment: The medicine should be used with caution in patients with liver or kidney problems, although no dosage adjustment is typically required.
  • Comorbidity Restriction: Patients at risk of osteoporosis require a baseline bone mineral density (BMD) assessment prior to starting treatment.
  • Drug Restriction: Aromasine must not be co-administered with estrogen-containing agents as this would counteract its intended pharmacological effect.

Eligibility is primarily limited to postmenopausal women and is prohibited for any woman who is premenopausal or currently pregnant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Aromasine (Exemestane), based strictly on government regulatory information.

Contraindicated and Exposure-Altering Combinations

The primary interaction constraints involve substances that either oppose the drug's intended action or significantly reduce its concentration in the body.

Interaction Type Interacting Substance / Class Official Constraint
Formal Contraindication Estrogen-Containing Agents Prohibited for co-administration; may interfere with Exemestane's pharmacologic action.
Exposure Reduction Strong CYP 3A4 Inducers May significantly decrease Exemestane exposure (AUC reduced by over 50% with Rifampicin).

Strong CYP 3A4 Inducers include medicines such as Rifampicin, Phenytoin, Carbamazepine, and Phenobarbital. The herbal product St. John's Wort is also documented as a potent inducer that may reduce efficacy.

Administration and Population Notes

The required dose of Aromasine must be administered once daily after a meal. This condition is specified to ensure optimal drug exposure and absorption. Caution is officially advised regarding the use of Exemestane in patients with pre-existing severe hepatic or renal impairment due to potential changes in drug clearance or interaction outcomes.

Mechanism of Action

Irreversible Inactivation of Aromatase Enzyme

Aromasin (Exemestane) is a steroidal aromatase inactivator that works by forming a permanent, covalent bond with the active site of the aromatase enzyme (CYP19A1). The drug acts as a "suicide inhibitor," chemically destroying the existing enzyme population responsible for the peripheral conversion of androgens into estrogens. The irreversible nature of the binding necessitates the de novo synthesis of new aromatase enzyme to restore activity, which defines the duration of the suppression.


⬇️ Significant Systemic Estrogen Suppression

The physiological consequence of this irreversible enzyme destruction is a significant systemic estrogen deprivation, typically resulting in an 85% to 95% reduction of circulating Estrone and Estradiol throughout the body. This suppression of the hormone is the core physiological change resulting from the mechanism of action. This mechanism, however, is subject to the body's natural endocrine feedback and is therefore overridden in premenopausal women due to the compensatory surge in ovarian hormone production.

Dosage and Administration Information

How to Use Aromasine — Official Administration Guidelines

Administration Scope

Route of administration: The medicine is available as a 25 mg film-coated tablet and is administered orally.

Dosing Schedule: The standard labeled dose is 25 mg taken once daily. This tablet must be taken after a meal to enhance systemic absorption. For patients concurrently receiving a strong CYP 3A4 inducer, such as rifampicin or phenytoin, the recommended dose is increased to 50 mg once daily.

Use Patterns and Population Rules

Duration of Therapy: For adjuvant use in early disease, treatment is typically continued for the completion of five consecutive years of hormonal therapy, often following a period of tamoxifen. For advanced disease, treatment should continue until tumor progression becomes evident.

Population-Specific Rules: Administration is restricted to individuals whose post-menopausal status has been ascertained. No dose adjustment is required for older adult patients or for those with mild to severe renal or hepatic impairment. Safety and efficacy have not been established for use in the pediatric population.

Procedural Guidance

Missed Dose Rules: If a patient misses a scheduled dose, they should take it as soon as they remember. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped; a patient must not take a double dose to compensate. The prescribed once daily frequency should be maintained thereafter.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aromasine

Aromasine (exemestane) was evaluated in research across several contexts of hormone-sensitive conditions. The research base primarily consists of Randomized Controlled Trials (RCTs), which are observed to be a benchmark for clinical evidence.


Evidence for Use in Advanced Breast Cancer

RCTs involved the medicine as an agent observed alongside other hormonal therapies in women with advanced, metastatic disease where progression had occurred. Studies monitored key measures like Objective Response Rate and Time to Progression. Research also examined Overall Survival, but data are still emerging regarding final results from extended observation periods.


Evidence for Use in Early Breast Cancer (Adjuvant Switch Therapy)

Large-scale, multi-national RCTs were applied in research exploring the strategy of switching to Aromasine after two to three years of initial tamoxifen therapy. The main focus of these trials was monitored through Disease-Free Survival and Recurrence-Free Survival. Comparative evidence is lacking regarding the outcomes of sequences or durations of therapy that differ from the primary trial protocols.


Evidence for Use in Breast Cancer Risk Reduction

Randomized, placebo-controlled trials were conducted in healthy postmenopausal women observed to be at a high risk for breast cancer. The primary outcome researched was the Incidence of Invasive Breast Cancer, and studies also monitored outcomes such as mammographic breast density. The results apply only to the populations studied, which were high-risk women as defined by specific criteria.


What Remains Uncertain in the Research Landscape

Despite the existence of high-quality RCTs, long-term effects are not fully established regarding ultimate Overall Survival across all indications due to the time required for complete follow-up. Additionally, data for certain subgroups remain insufficient, and the findings describe group patterns, not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Aromasine (FAQ)


Q: Is Aromasine considered a chemotherapy drug?

According to official product information, this medicine is classified as an aromatase inhibitor and an antineoplastic agent. This type of medicine works by targeting hormones to reduce estrogen levels in postmenopausal women, which is often referred to as endocrine therapy. This mechanism differs from the way traditional cytotoxic chemotherapy drugs work.


Q: What ingredients in Aromasine could potentially cause an allergic reaction?

Official product labeling states that the medicine is contraindicated if a person has a known hypersensitivity to the active substance or any of the inactive ingredients, also called excipients. Excipients listed on some labels include sucrose, titanium dioxide, and methyl parahydroxybenzoate (methylparaben). This ingredient is officially documented as a substance that may cause allergic reactions.


Q: Are there any specific food or diet restrictions while on Aromasine?

Regulatory information does not mandate specific food restrictions while using this medicine. However, official guidance states that the tablet is administered once daily after a meal. This condition is specified because taking the dose with food helps enhance the systemic absorption of the drug.


Q: Are regular blood tests generally recommended while taking Aromasine?

Official regulatory guidance indicates that assessment of 25-hydroxy vitamin D levels should occur prior to starting treatment. Furthermore, because of the potential for bone changes over time, monitoring of bone mineral density (BMD) is generally recommended for patients at risk of osteoporosis.


Q: Does Aromasine cause weight gain or loss?

While regulatory documentation for the medicine does not explicitly list weight gain or weight loss as a common effect, it does list increased appetite as a common potential side effect.


Q: Can Aromasine affect my mood or cause depression?

Studies and official product information list changes in mood as common potential side effects. These include depression, anxiety, and insomnia (trouble sleeping).


Q: Does Aromasine work in the same way as Tamoxifen?

Official product information classifies this drug as an aromatase inhibitor, which works by chemically inactivating the aromatase enzyme. This mechanism is distinct from that of tamoxifen, which is a different type of endocrine therapy often used in an earlier phase of treatment.


Q: Does Aromasine interact with common vitamin or mineral supplements?

Official regulatory guidance indicates that a routine assessment of Vitamin D levels is considered before starting therapy. Official product information includes a statement that certain herbal products, such as St. John’s Wort, can significantly decrease the amount of medicine absorbed, potentially reducing its effect.


Q: How long does it take for Aromasine to begin having its described effect?

Regulatory pharmacokinetic data indicates that the intended therapeutic effect, which is the maximal suppression of circulating estrogen levels, is described as occurring 2 to 3 days after dosing.


Q: If someone stops taking Aromasine, how long does the drug typically remain in the system?

According to regulatory pharmacokinetic information, the drug is cleared from the systemic circulation with a terminal plasma half-life of approximately 24 hours. This time frame describes the rate at which the concentration of the drug is reduced in the body.


Q: Is Aromasine available as a generic drug (Exemestane)?

This medicine is available under the brand name AROMASIN and also in its generic form, which is called exemestane. Regulatory sources confirm that the generic form is available from multiple manufacturers.


Q: Have there been studies examining the connection between Aromasine and heart health?

Studies monitored the incidence of heart-related issues, which are officially documented as potential safety considerations. Clinical trials examined the incidence of cardiac ischemic events, which include myocardial infarction (heart attack) and angina.

How should Aromasine be stored and disposed of?

How to Store and Dispose of Aromasin (Exemestane)

The storage and disposal of Aromasin (exemestane) must comply strictly with official regulatory requirements to ensure the product’s quality and safety.


Official Storage Conditions

Storage Requirement Details
Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep in the original container or packaging to maintain integrity.
Child Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Aromasin should not be thrown into household trash or poured into wastewater. Disposal must be conducted according to local regulations for pharmaceutical waste. Individuals should return unwanted medication to a pharmacist or utilize a local drug take-back program for proper environmental management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aromasine found in:

A-Z Index: